Prudential Financial Inc. boosted its stake in Cepheid (NASDAQ:CPHD) by 36.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 145,897 shares of the company’s stock after buying an additional 38,900 shares during the period. Prudential Financial Inc. owned 0.20% of Cepheid worth $4,486,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Teacher Retirement System of Texas raised its position in shares of Cepheid by 13.8% in the second quarter. Teacher Retirement System of Texas now owns 10,114 shares of the company’s stock valued at $311,000 after buying an additional 1,226 shares during the period. SECOR Capital Advisors LP increased its stake in shares of Cepheid by 126.6% in the second quarter. SECOR Capital Advisors LP now owns 17,857 shares of the company’s stock valued at $549,000 after buying an additional 9,977 shares in the last quarter. UBS Asset Management Americas Inc. increased its stake in shares of Cepheid by 366.8% in the second quarter. UBS Asset Management Americas Inc. now owns 991,633 shares of the company’s stock valued at $30,493,000 after buying an additional 779,199 shares in the last quarter. Suffolk Capital Management LLC increased its stake in shares of Cepheid by 3.4% in the second quarter. Suffolk Capital Management LLC now owns 74,156 shares of the company’s stock valued at $2,280,000 after buying an additional 2,429 shares in the last quarter. Finally, Oppenheimer & Co. Inc. increased its stake in shares of Cepheid by 2.1% in the second quarter. Oppenheimer & Co. Inc. now owns 11,319 shares of the company’s stock valued at $348,000 after buying an additional 236 shares in the last quarter. 95.27% of the stock is currently owned by institutional investors and hedge funds.
Cepheid (NASDAQ:CPHD) opened at 52.66 on Monday. Cepheid has a one year low of $25.09 and a one year high of $53.91. The firm has a 50-day moving average of $49.52 and a 200-day moving average of $36.23. The company’s market cap is $3.84 billion.
Cepheid (NASDAQ:CPHD) last released its earnings results on Thursday, July 28th. The company reported $0.05 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.14) by $0.19. The firm earned $146 million during the quarter, compared to analyst estimates of $145.82 million. Cepheid had a negative net margin of 8.78% and a negative return on equity of 10.20%. The business’s revenue was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.06) EPS. On average, analysts predict that Cepheid will post $0.33 EPS for the current year.
Several analysts recently issued reports on the company. JPMorgan Chase & Co. increased their price target on Cepheid from $32.00 to $35.00 and gave the company a “neutral” rating in a report on Friday, July 29th. BTIG Research downgraded Cepheid from a “buy” rating to a “neutral” rating in a report on Wednesday, September 7th. Zacks Investment Research upgraded Cepheid from a “hold” rating to a “strong-buy” rating and set a $41.00 price target for the company in a report on Monday, August 1st. TheStreet upgraded Cepheid from a “sell” rating to a “hold” rating in a report on Wednesday, September 28th. Finally, Barclays PLC increased their price target on Cepheid from $36.00 to $52.00 and gave the company an “equal weight” rating in a report on Wednesday, September 7th. Sixteen investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $41.36.
In other news, VP Scott A. Campbell sold 746 shares of the business’s stock in a transaction dated Thursday, August 4th. The shares were sold at an average price of $36.71, for a total transaction of $27,385.66. Following the transaction, the vice president now owns 10,721 shares in the company, valued at approximately $393,567.91. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 4.16% of the company’s stock.
Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company’s systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures.
Want to see what other hedge funds are holding CPHD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cepheid (NASDAQ:CPHD).
Receive News & Ratings for Cepheid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cepheid and related companies with MarketBeat.com's FREE daily email newsletter.